It was an honor to have GI radonc legend, Prof. Trevor Leong, at the @USThospital BCI Annual Meeting! Your expertise was the highlight, and your time with our trainees was priceless. See you in Manila again soon, maybe next time w/ @pixiepk1! @PeterMacRadOnc @UST1611official

The kiss 💋 between nab-paclitaxel / gem and FOLFINIRNOX ?! ♥️ Neoadjuvant regimens combined in resectable 💉 RCT 324 pts vs. Upfront surgery median EFS 15 vs. 10 months? 🧐 Doubts about control group, but again in the direction of neoadjuvant to all! https://t.co/YCkQKFTo9k

🧠 You can shrink the tumour—but not the tumour bed. New RAPIDO analysis in BJS 2025 shows why small margins after TNT can turn dangerous 👇 💡 Trial: RAPIDO (n = 920, LARC) 🎯 TNT = 5×5 Gy + 6 CAPOX / 9 FOLFOX → TME vs CRT = 25–28×1.8–2 Gy + capecitabine → TME 📊 8-year

🔬 Critical Evaluation of TNT in LARC 🔗 https://t.co/sLoLUmvHYZ 🧬 Review of RAPIDO, PRODIGE-23, POLISH II & STELLAR 💊 Small DFS gain · OS benefit uncertain · Added toxicity 📊 CRT remains standard; biomarkers needed for selection #DraMartinezLago #GItumors

It’s out!!! 🔥🔥🔥 The PREOPANC-2 is in @TheLancetOncol Neoadjuvant FOLFIRINOX 🤜🤛 Gemcitabine based chemoradiotherapy in resecatble / BR ⚖️ No difference in overall survival 😰 Serious adverse events 40% 👍 Both regimens may be considered https://t.co/9nfnPUyhCR

First of 2 consensus statements coming out for #NPC. This one is an effort undertaken with most of the participants from #LMIC settings. Excellent inclusivity effort from @WarrenBacorro and team. https://t.co/b8KBnquYgP

Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial) 💥OS after active surveillance was not inferior to standard surgery at 2 years https://t.co/uq7mH21pUC

Sharing our work from @PeterMacRadOnc published @ClinOncology, reporting that neoadjuvant CRT can be clinically useful for highly selected colon cancers. Our results support the Zhang ph 3 study which showed efficacy of CRT for unresectable colon cancers. https://t.co/EjdSPxN3wq

🚨SCIENCE Ph3 RCT🚨 🔥Check this one out🔥 cT2-4N0-3, T1N2-3 Eso SCC 1️⃣neo Carbo + nabPaclitaxel + Sintilimab 2️⃣nCRT 41.4/23) wCarbo-taxol + Sintilimab 3️⃣nCRT ✅⬆️⬆️pCR CRT vs chemo (13% with chemo) ✅Sintilimab + CRT vs CRT ⬆️ pCR (60% v 47%) without added AEs #GI25 @ASCO

🚨ESOPEC Pub has landed!🚨 See data review below! For now, "standard" will appropriately shift to peri-operative FLOT BUT we should not be satisfied as outcomes remain suboptimal Ongoing ❓❓ - does TNT (FLOT + CRT) offer further benefit? - is it time to consider organ

External Beam Radiation therapy After Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for Treatment of Inoperable Hepatocellular Carcinoma: A Randomized Phase 3 Trial - International Journal of Radiation Oncology, Biology, Phys

❗️ RCT of proton RT vs TACE in HCC mPFS for PBT vs TACE was not reached vs. 12 months, p = .002; with a whopping HR 3.62 (1.62–8.05) TACE is a very poor treatment 👎

Proud to see RTOG1112 RCT published!. Thanks to so many who helped make this possible. #teamwork ‘Hope the next #SBRT #HCC trials are completed much faster. @NRGonc @TedHong9 @Dr_AliHosni @ArndtVogel @aislingbarryro Nice summary of the trial below from @NiuSanford

🚨 🚨 RCT of SBRT vs RFA for recurrent small HCC HR for local progression free survival a whopping 0.45 (0.95 CI 0.24-0.87) with SBRT vs RFA More data of the inferiority of IR ablation for HCC https://t.co/cafvrh0lGp

RACE-GB is out! Congrats to authors for FIRST RCT of RT in gallbladder cancer. N=135 w unresectable GBC, after 4c chemo, addition of RT (vs. obs) improved OS from 4 to 10 months. Several limitations (single center, chemo gem/cis & 4 mo) but OS benefit shouldn’t be ignored.

@5_utr Fantastic! Here is the HR for SBRT vs. TACE in our work. EBRT was associated with improved PFS over TACE (HR: 0.37, 95% CI = 0.23-0.60; I2 = 0%). Here is the abstract from #ASTRO24, the full publication was just accepted in Cancer today!

Another setting where SBRT underutilized IMO in HCC is bridge to transplant. I am convinced w modern tech, SBRT can safely prevent local progression in most. Study shows similar transplant outcomes post SBRT/TACE/RFA, despite SBRT pts w worse liver fxn https://t.co/svrVvwzjy2

Just in time for #CTOS2024: Thrilled to share SU2C-SARC032 (NCT03092323), a randomized trial of pembrolizumab in Stage 3 extremity soft tissue sarcoma, now published @TheLancet! https://t.co/P9lAyTX9NF 1/13 @SARCtrials @SU2C @ctosociety @RadMedPM @pmcancercentre @UHN @UofTDRO

Congrats to Prof Trevor Leong and TOPGEAR trial investigators on publication of significant findings at #ESMO24 and in @NEJM this weekend. We're thrilled to have collaborated on this important trial with @GICancer and others.

In this study of patients receiving combined locoregional and immunotherapies (LRT-IO) for unresectable HCC, 46% had complete response (CR) and 75% remained alive at 3 years. Watch and wait was shown feasible in CR patients after LRT-IO. https://t.co/tAZWEIIWdX